Clinical Association between Phospho-AKT Expression with Clinicopathological Characteristics of Gastrointestinal Cancer Patients: A Meta-Analysis

2020 ◽  
Vol 30 (4) ◽  
pp. 299-309
Author(s):  
Hossein Abdeahad ◽  
Afsane Bahrami ◽  
Majid Khazaei ◽  
Gordon A. Ferns ◽  
Marjan Erfani ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Gastrointestinal Cancer ◽  
Meta Analysis ◽  
Clinicopathological Characteristics

scholarly journals miR-19 Is a Potential Clinical Biomarker for Gastrointestinal Malignancy: A Systematic Review and Meta-analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Xiaoxu Song ◽  
Wenyi Li ◽  
Peng Shen ◽  
Bing Bai ◽  
Lin-Lin Cao
Keyword(s):  
Cancer Patients ◽  
Gastrointestinal Cancer ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Clinicopathological Characteristics ◽  
Clinical Value ◽  
Gastrointestinal Malignancy ◽  
Free Survival ◽  
Clinical Biomarker ◽  
Disease Free

Objectives. To assess the expression and clinical value of miR-19 in gastrointestinal malignancy. Setting. Embase, Web of Science, PubMed, and other databases were retrieved to screen out relevant studies until December 31, 2019. Participants. Gastrointestinal cancer patients with the description of miR-19 expression, as well as the correlation between miR-19 and clinicopathological characteristics or prognosis. Main Outcome Measures. Pooled odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) was obtained to determine miR-19 expression in gastrointestinal malignancy and the association between miR-19 and patients’ clinical characteristics and survival. Results. Thirty-seven studies were included in this study. miR-19 levels in gastrointestinal malignancy, especially in hepatocellular (OR=4.88, 95%  CI=2.38‐9.99), colorectal (OR=4.81, 95%  CI=2.38‐9.72), and pancreatic (OR=5.12, 95%  CI=2.43‐10.78) cancers, were significantly overexpressed, and miR-19 was tightly related to some clinicopathological characteristics, such as lymph node metastasis (OR=1.74, 95%  CI=1.05‐2.86). Although gastrointestinal cancer patients with low and high miR-19 expression had comparable OS (overall survival) and DFS (disease-free survival), subgroup analyses showed that patients with high miR-19 presented better DFS than those with low miR-19 in liver cancer (HR=0.46, 95%  CI=0.30‐0.71). Conclusions. miR-19 might be a potential progression and prognostic biomarker for gastrointestinal malignancy.

scholarly journals Association of Caveolin-1 Expression With Prostate Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 10 ◽  
Author(s):  
Pei Chen ◽  
Yu-ling Zhang ◽  
Bai Xue ◽  
Guo-ying Xu
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Specific Antigen ◽  
Intraepithelial Neoplasia ◽  
Clinicopathological Characteristics ◽  
Clinicopathological Feature ◽  
Caveolin 1 ◽  
The Relationship

PurposeThe prognostic value of caveolin-1 in prostate cancer remains uncertain. Hence, this meta-analysis was performed to evaluate the prognostic value of caveolin-1 in prostate cancer, as well as ascertain the relationship between caveolin-1 expression and clinicopathological characteristics of prostate cancer patients.MethodsThe PubMed, Embase, Chinese National Knowledge Infrastructure and Chinese Biology Medicine databases were electronically searched to retrieve published studies on caveolin-1 expression in prostate cancer. After study selection and data extraction, the meta-analysis was conducted using Review manager 5.3 software. Odds ratio (OR) with 95% confidence interval (CI) was used to estimate the pooled effect. Funnel plot was used to assess publication bias.ResultsA total of ten studies were enrolled, which included 3976 cases of prostate cancer, 72 cases of high-grade intraepithelial neoplasia (HGPIN), and 157 normal controls. Results of the meta-analysis showed that the positive rate of caveolin-1 expression in prostate cancer was 18.28 times higher than that in normal control (OR= 18.28, 95% CI: 9.02–37.04, p<0.01), and 4.73 times higher than that in HGPIN (OR= 4.73, 95% CI: 2.38–9.42, p<0.01). The relationship between caveolin-1 and clinicopathological characteristics of prostate cancer showed that the differences in caveolin-1 expression in patients with prostate-specific antigen (PSA) >10 vs. ≤ 10 (OR=2.09, 95% CI: 1.35–3.22, p<0.01), differentiation degree low vs. medium/high (OR=2.74, 95% CI: 1.84–4.08, p<0.01), TNM stage T3+T4 vs. T1+T2 (OR=2.77, 95% CI: 1.78–4.29, p<0.01), and lymph node metastasis present vs. absent (OR=2.61, 95% CI: 1.84–3.69, p<0.01) were statistically significant. The correlation analysis between caveolin-1 and the survival time of patients with prostate cancer demonstrated that caveolin-1 was closely related to the prognosis of prostate cancer patients (HR=1.50, 95% CI: 1.28–1.76, p<0.01).ConclusionCaveolin-1 is overexpressed in prostate cancer, which can serve as a risk factor and adverse clinicopathological feature of prostate cancer. Caveolin-1 can also predict poor survival in prostate cancer patients after radical prostatectomy.

scholarly journals Glutathione S-transferases genes variants and chemotherapy efficacy in gastrointestinal cancer patients: a meta-analysis based on 50 pharmacogenetic studies

2019 ◽  
Vol 10 (13) ◽  
pp. 2915-2926 ◽  
Author(s):  
Yuesheng Sun ◽  
Jianghua Pan ◽  
Xiaochun Tong ◽  
Ende Chen ◽  
Wangxin Yan ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Gastrointestinal Cancer ◽  
Meta Analysis ◽  
Glutathione S Transferases ◽  
Chemotherapy Efficacy

scholarly journals Immunohistochemical Determination of ATAD2 Protein Overexpression for Predicting Prognostic Value in Patients with Different Types of Cancer: A Meta-Analysis

2019 ◽  
pp. 280-289
Author(s):  
Jiang S ◽  
Liu J ◽  
Chen X ◽  
Zheng X ◽  
Ruan J ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Meta Analysis ◽  
Hepatocellular Cancer ◽  
Tumor Stage ◽  
Clinicopathological Characteristics ◽  
Protein Overexpression ◽  
Immunohistochemical Studies ◽  
Rr Relative Risk ◽  
The Relationship

Background: Increasing number of studies has reported that Atpase family AAA domain-containing 2 (ATAD2) is nuclear coactivator, which is associated with tumor cell proliferation and invasion. Previous studies have demonstrated conflicting results on the relationship between high ATAD2 expression and clinicopathological characteristics of the tumors or patients’ survival outcomes. Considering the discordant results of published studies, we performed a metaanalysis to evaluate the ATAD2 expression in predicting prognosis, and to assess the relationship between high ATAD2 expression and clinicopathological parameters.Methods: We systematically searched electronic database of PubMed, Web of Science and Embase, and selected all immunohistochemical studies of hepatocellular cancer specimens for ATAD2, to analyze the relationship between high ATAD2 expression and prognosis of hepatocellular cancer patients. Pooled data of eligible studies together from individual studies and analyzed data using STATA software to perform this meta-analysis.Results: A total of 5 studies with 719 liver cancer patients were included. ATAD2 protein overexpression wassignificantly correlated with poorer overall survival (HR 3.53, 95% CI: 1.87-6.63, P = 0.000). In addition, high ATAD2 expression was also negatively related with tumor stage [RR, relative risk: 1.46 (95% CI: 1.30-1.64); P < 0.001], as well as tumor size [RR: 1.23(95% CI: 1.06-1.43); P < 0.001], and tumor recurrence [RR: 1.34 (95% CI: 1.05-1.72); P < 0.001].Conclusions: These data suggested that immunohistochemical determination of ATAD2 Protein might be aprognostic biomarker for the patients of hepatocellular cancer.

scholarly journals Prognostic role of SIRT6 in gastrointestinal cancers: a meta-analysis

Open Medicine ◽  
2020 ◽  
Vol 15 (1) ◽  
pp. 358-365
Author(s):  
Li Shi ◽  
Ying Wang ◽  
Timothy Bonney Oppong ◽  
Xiaoli Fu ◽  
Haiyan Yang ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Gastrointestinal Cancer ◽  
Web Of Science ◽  
Meta Analysis ◽  
Relevant Literature ◽  
Critical Role ◽  
Clinicopathological Parameters ◽  
Gastrointestinal Cancers ◽  
Potential Biomarker

AbstractSirtuin 6 (SIRT6) plays a critical role in the progression and development of gastrointestinal cancers. However, the association between SIRT6 expression and clinicopathological parameters and prognosis in gastrointestinal cancer patients remains inconclusive. Consequently, we conducted this meta-analysis to evaluate the importance of SIRT6 expression in various types of gastrointestinal cancers. PubMed, EMBASE, and Web of Science databases were systematically searched to screen the relevant literature. The reported or estimated hazard ratio (HR) and odds ratio (OR) and their corresponding 95% confidence interval (CI) were pooled to assess the strength of the association. Nine studies involving 867 patients were included in the meta-analysis. Overall analysis showed that high SIRT6 expression was related to better overall survival in gastrointestinal cancers (HR = 0.62, 95% CI = 0.47–0.82). High SIRT6 expression was also related to a favorable tumor node metastasis (TNM) stage (OR = 0.44, 95% CI = 0.28–0.70) among gastrointestinal cancer patients. Our meta-analysis revealed that high SIRT6 expression might be a potential biomarker predicting better prognosis in gastrointestinal cancers, which may offer options for gastrointestinal cancer treatment.

scholarly journals Long noncoding RNA SNHG12 is a potential diagnostic and prognostic biomarker in various tumors

2020 ◽  
Author(s):  
XinZhuang Wang ◽  
Qiuyi Jiang ◽  
Cheng Zhang ◽  
Quan Yang ◽  
Lixiang Wang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Noncoding Rna ◽  
Malignant Tumors ◽  
Meta Analysis ◽  
Predictive Biomarker ◽  
Tumor Stage ◽  
Clinicopathological Characteristics ◽  
Cerebrovascular Diseases ◽  
High Expression

Abstract Background. Tumors are the second most common cause of death in humans worldwide, second only to cardiovascular and cerebrovascular diseases. Although methods and techniques for the treatment of tumors continue to improve, the effect is not satisfactory. These may lack effective therapeutic targets. This study aimed to evaluate the value of SNHG12 as a biomarker in the prognosis and clinical characteristics of various cancer patients.Methods.We analyzed SNHG12 expression and plotted the survival curves of all cancer samples in the TCGA database using the GEPIA tool. Then, we searched for eligible papers up to April 1, 2019 in databases. Next, the data were extracted from studies examining SNHG12 expression, overall survival and clinicopathological features in patients with malignant tumors. We used Review Manager 5.3 and Stata 15 software to analyze the statistical data.Results.In the TCGA database, abnormally high expression of SNHG12 in tumor samples indicates that the patient has a poor prognosis. Results of meta-analysis is that SNHG12 high expression is related to low overall survival (HR=2.72, 95% CI=1.95-3.8, P<0.00001), high tumor stage (OR=3.94, 95% CI=2.80-5.53, P<0.00001), high grade (OR=2.04, 95% CI=1.18-3.51, P=0.01), distant metastasis (OR=2.20, 95% CI=1.40-3.46, P=0.0006), tumor size (OR=2.79, 95% CI=1.89-4.14, P<0.00001) and lymph node metastasis (OR=2.66, 95%CI=1.65-4.29, P<0.0001).Conclusions.Our study confirmed that the high expression level of SNHG12 is closely related to the clinicopathological characteristics and prognosis of patients and is a new predictive biomarker for various cancer patients.

scholarly journals Long Noncoding RNA SNHG12 is a Potential Diagnostic and Prognostic Biomarker in Various Tumors

2020 ◽  
Author(s):  
XinZhuang Wang ◽  
Qiuyi Jiang ◽  
Cheng Zhang ◽  
Quan Yang ◽  
Lixiang Wang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Noncoding Rna ◽  
Malignant Tumors ◽  
Meta Analysis ◽  
Predictive Biomarker ◽  
Tumor Stage ◽  
Clinicopathological Characteristics ◽  
Cerebrovascular Diseases ◽  
High Expression

Abstract Background. Tumors are the second most common cause of death in humans worldwide, second only to cardiovascular and cerebrovascular diseases. Although methods and techniques for the treatment of tumors continue to improve, the effect is not satisfactory. These may lack effective therapeutic targets. This study aimed to evaluate the value of SNHG12 as a biomarker in the prognosis and clinical characteristics of various cancer patients.Methods. We analyzed SNHG12 expression and plotted the survival curves of all cancer samples in the TCGA database using the GEPIA tool. Then, we searched for eligible papers up to April 1, 2019 in databases. Next, the data were extracted from studies examining SNHG12 expression, overall survival and clinicopathological features in patients with malignant tumors. We used Review Manager 5.3 and Stata 15 software to analyze the statistical data.Results. In the TCGA database, abnormally high expression of SNHG12 in tumor samples indicates that the patient has a poor prognosis. Results of meta-analysis is that SNHG12 high expression is related to low overall survival (HR=2.72, 95% CI=1.95-3.8, P<0.00001), high tumor stage (OR=3.94, 95% CI=2.80-5.53, P<0.00001), high grade (OR=2.04, 95% CI=1.18-3.51, P=0.01), distant metastasis (OR=2.20, 95% CI=1.40-3.46, P=0.0006), tumor size (OR=2.79, 95% CI=1.89-4.14, P<0.00001) and lymph node metastasis (OR=2.66, 95%CI=1.65-4.29, P<0.0001).Conclusions. Our study confirmed that the high expression level of SNHG12 is closely related to the clinicopathological characteristics and prognosis of patients and is a new predictive biomarker for various cancer patients.

Sign in / Sign up

Export Citation Format

Share Document